Abstract

Center for Biologics Evaluation and Research enhances and supports regulatory decision-making and policy development. This work contributes to our regulatory mission, advances medical product development, and supports Food and Drug Administration’s regulatory response to public health crises. This review presents some examples of our diverse scientific work undertaken in recent years to support our regulatory and public health mission.

Highlights

  • The Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA) has regulatory oversight of blood, tissues, and complex medical products that include vaccines, allergenic products, blood-derived products, certain diagnostics and devices, live biotherapeutics, and novel medical products, such as stem cell-derived products, and other cell and gene therapies.The complex biological products regulated by CBER present a variety of challenges:(1) The challenge of ensuring product sterility, i.e., the absence of unwanted infectious agents, is compounded with the use of biological materials in the manufacture of biological products

  • The complex biological products regulated by CBER present a variety of challenges: [1] The challenge of ensuring product sterility, i.e., the absence of unwanted infectious agents, is compounded with the use of biological materials in the manufacture of biological products

  • A recent example of the work being performed by the consortium is the development of a new method to predict differentiated functional capacity of human mesenchymal stem cells after osteogenic induction

Read more

Summary

Frontiers in Medicine

This work contributes to our regulatory mission, advances medical product development, and supports Food and Drug Administration’s regulatory response to public health crises. This review presents some examples of our diverse scientific work undertaken in recent years to support our regulatory and public health mission

INTRODUCTION
Detecting Contaminants in Biological Products
Improving Quality and Consistency of Biological Products
Reference Materials and Standards
Learning from Medical Products That Fail in Clinical Trials
PREPARING FOR FUTURE REGULATORY AND PUBLIC HEALTH CHALLENGES
CONCLUSION
Findings
AUTHOR CONTRIBUTIONS

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.